Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
phase 3
Biotech
AbbVie bispecific shows promise in ph. 3 multiple myeloma trial
The monthly dosing schedule demonstrated low rates of cytokine release syndrome and fatal infections.
Marissa Russo
Sep 3, 2026 9:20am
Ultragenyx fails ph. 3 Angelman test as shares tumble
Sep 3, 2026 7:10am
How Biohaven is keeping its 'feet to the fire'
Feb 20, 2026 10:30am
Lundbeck’s preventative migraine IV sees success in ph. 2
Feb 12, 2026 1:25pm
US vaccine landscape ‘100%’ impacting business: Bancel
Jan 23, 2026 1:26pm
CEPI to fund Moderna's pandemic flu trial after HHS walked away
Dec 18, 2025 9:40am
